Reacción a "A wireless electronic device for treating diabetes and obesity without drugs has been tested in mice"

The fact that this work is to be published in Science made a positive impression on me, and I approached it with very high expectations—especially regarding its potential for clinical application. Indeed, I find it an ingenious and well-developed piece of work as a proof of concept. The authors carefully examine how the device functions, demonstrating that it successfully reduces both glucose levels and body weight in mice with diabetes and obesity. The implant uses electricity to convert a portion of the glucose into a substance that the body can then excrete through urine; connected to a sensor, it adjusts its activity based on the prevailing sugar levels. There is prior research in this area, including a study by the same group published in 2023 that combined glucose consumption with insulin release. The current contribution lies in the ability to electrically control this conversion process without the need for insulin or other glucose-lowering drugs.

That said, enthusiasm should be tempered with caution. The study was conducted on small groups of mice with a specific genetic alteration, which does not capture the full diversity of diabetes and obesity as they manifest in humans. The treatment was evaluated over six weeks, and the fully automated system over twelve days. It remains to be seen whether the implant can function safely over a long period, and how it might perform in cases where kidney function—responsible for eliminating the reaction byproduct—is compromised. While the absence of adverse effects in these experiments is promising, it does not yet guarantee safety in humans. In the context of diabetes and obesity, success must also be measured by a reduction in complications and an improved quality of life. It is an intriguing approach, though my initial expectations regarding its clinical application must, for now, await the next stages of development.